查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1698493

次世代定序仪市场：2025-2030 年预测

Next Generation Sequencers Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计次世代定序仪(NGS) 市场在预测期内（即 2025-2030 年）的复合年增长率为 7.35%。

次世代定序仪是一种大规模平行定序技术，具有可扩展性、超高通量和速度。它可用于确定完整基因组中核苷酸的顺序。 DNA定序是整个定序方法中最重要的步骤之一，涉及为后续定序反应准备材料。在全球范围内，NGS正逐渐被纳入临床实验室分析、检测和疾病诊断。药物基因组学已做出了巨大努力来加快药物发现过程。基因组图谱计划、次世代定序仪应用、医疗保健支出和技术改进是预测期内推动次世代定序仪市场成长的主要因素。

市场趋势：

  • 次世代定序仪市场的成长：由于能够透过碱基定序对整个基因组进行定序，次世代定序仪市场正在不断扩大。过程中的关键步骤是 DNA 预测序，它为后续的定序反应准备样本，是任何定序通讯协定的基石。在全球范围内，NGS 越来越多地融入医学实验室分析、疾病评估和诊断。在药物基因组学中，NGS 被广泛用于加速药物发现。行业参与者旨在提高诊断能力的重大创新和发展预计将成为未来几年市场发展的主要驱动力。例如，2023 年 3 月，SOPHiA GENETICS 与 Qiagen 合作，利用 NGS 推进肿瘤分析。此次合作将 QIAseq 试剂技术与 SOPHiA DDM 平台相结合，使客户能够透过 SOPHiA DDM™ 存取处理过的 QIAseq 面板 - SOPHiA DDM™ 是一种云端基础的工具，可分析来自各种来源的数据以解锁新的研究见解。最初，伙伴关係将专注于同源重组修復 (HRR)，这是一种生物标记测试，用于识别可能对肿瘤学中的 PARP 抑制剂有反应的突变肿瘤，利用 QIAseq Targeted DNA Pro Panel 进行体细胞突变检测。
  • 区域市场洞察：全球次世代定序仪市场分为北美、南美、欧洲、中东和非洲以及亚太地区。北美已成为全球领先的 NGS 市场，预计未来几年仍将保持这一主导地位。 NGS 技术在常规临床诊断中的日益普及是一个主要驱动因素。该地区的市场扩张受到慢性病和感染疾病病率上升、基因组学投资增加以及主要行业参与者取得重大进展等因素的进一步支持。例如，加拿大癌症协会估计，2024 年将有 6,600 名加拿大人被诊断出罹患白血病。同时，美国卫生与公共服务部报告同年新增 62,770 例病例，占所有新癌症诊断的 3.1%。日益加重的疾病负担刺激了对创新检测和诊断解决方案的需求，推动了整个预测期内的市场成长。

本报告涉及的主要企业包括 Quest Diagnostics Incorporated、ARUP Laboratories、Applied Biological Materials, Inc. (ABM)、Novogene Co. Ltd.、Azenta Life Sciences (GENEWIZ) 和 NanoString。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 适用范围广：对于新兴企业、研究机构、顾问公司、中小企业和大型企业来说，它都是实用且具有成本效益的。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法规结构、趋势分析
  • 竞争市场条件、策略与市场占有率分析
  • 对各细分市场和地区（包括国家）的收益成长和预测评估
  • 公司简介（策略、产品、财务资讯、主要发展等）

目录

第一章 引言

  • 市场概览
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

第五章次世代定序仪市场（按产品）

  • 介绍
  • 产品
  • 服务

第六章次世代定序仪市场（依技术）

  • 介绍
  • 边合成边定序
  • 离子半导体定序
  • 单分子即时定序
  • 奈米孔定序
  • 其他的

第七章次世代定序仪市场（依应用）

  • 介绍
  • 诊断
  • 药物研发
  • 生物标记发现
  • 农业和动物研究
  • 其他的

第八章次世代定序仪市场（依最终用户）

  • 介绍
  • 医院和诊所
  • 製药和生物技术公司
  • 学术和研究机构
  • 其他的

第九章次世代定序仪市场（按地区）

  • 世界概况
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十一章 公司简介

  • Quest Diagnostics Incorporated
  • ARUP Laboratories
  • Applied Biological Materials, Inc.（ABM）
  • Novogene Co., Ltd.
  • Azenta Life Sciences（GENEWIZ）
  • NanoString
  • Illumina, Inc.
  • PacBio
  • Qiagen
  • Thermo Fisher Scientific
简介目录
Product Code: KSI061615484

The next-generation sequencers market is expected to grow at a CAGR of 7.35% during the projected period from 2025 to 2030.

Next-generation sequencing (NGS) is a massively parallel sequencing technology that enables scalability, ultra-high throughput, and quick speed. It can be used to establish the order of the nucleotides in the complete genome. DNA pre-sequencing is one of the most crucial steps in the entire sequencing methodology, which involves preparing the material for the following sequencing reaction. Globally, NGS is being gradually included in clinical laboratory analysis, testing, and illness diagnosis. Pharmacogenomics has made extensive efforts to speed up the drug discovery process. Genome mapping programs, next-generation sequencing applications, healthcare spending, and technology improvements are the main factors driving the next-generation sequencers market growth during the projected period.

Market Trends:

  • Growth of the Next-Generation Sequencing Market: The next-generation sequencing (NGS) market is expanding due to its ability to sequence entire genomes by determining nucleotide sequences. A critical step in this process is DNA pre-sequencing, which prepares samples for subsequent sequencing reactions, making it a cornerstone of the sequencing protocol. Worldwide, NGS is increasingly integrated into medical laboratory analysis, disease evaluation, and diagnostics. In pharmacogenomics, NGS is widely utilized to accelerate drug discovery. Key innovations and developments by industry players aimed at enhancing diagnostic capabilities are expected to drive significant market growth in the coming years. For example, in March 2023, SOPHiA GENETICS partnered with Qiagen to advance tumor analysis through NGS. This collaboration combined QIAseq reagent technology with the SOPHiA DDM platform, enabling customers to access QIAseq panels processed via SOPHiA DDM(TM)-a cloud-based tool that analyzes data from various sources to unlock new research insights. Initially, the partnership focuses on homologous recombination repair (HRR), a biomarker test identifying tumors with mutations that may respond to PARP inhibitors in oncology, utilizing QIAseq Targeted DNA Pro panels for somatic variant detection.
  • Regional Market Insights: The global next-generation sequencers market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is projected to emerge as a leading market for NGS worldwide and is expected to maintain this dominance for several years. The growing adoption of NGS technology in routine clinical diagnostics is a key driver. Market expansion in this region is further supported by factors such as the increasing incidence of chronic and infectious diseases, rising investments in genomics, and significant advancements by major industry players. For instance, the Canadian Cancer Society estimates that 6,600 Canadians will be diagnosed with leukemia in 2024, while the US Department of Health and Human Services reported 62,770 new cases in the same year, representing 3.1% of all new cancer diagnoses. This rising disease burden is fueling demand for innovative detection and diagnostic solutions, propelling market growth throughout the forecast period.

Some of the major players covered in this report include Quest Diagnostics Incorporated, ARUP Laboratories, Applied Biological Materials, Inc. (ABM), Novogene Co., Ltd., Azenta Life Sciences (GENEWIZ), NanoString, among others.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Next Generation Sequencers Market is segmented and analyzed as follows:

By Offering

  • Product
  • Services

By Technology

  • Sequencing By Synthesis
  • Ion Semiconductor Sequencing
  • Single-molecule Real-time Sequencing
  • Nanopore Sequencing
  • Others

By Application

  • Diagnostics
  • Drug Discovery
  • Biomarker Discovery
  • Agriculture & Animal Research
  • Others

By End-User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academics & Research Institutes
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. NEXT GENERATION SEQUENCERS MARKET BY OFFERING

  • 5.1. Introduction
  • 5.2. Product
  • 5.3. Services

6. NEXT GENERATION SEQUENCERS MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Sequencing By Synthesis
  • 6.3. Ion Semiconductor Sequencing
  • 6.4. Single-molecule Real-time Sequencing
  • 6.5. Nanopore Sequencing
  • 6.6. Others

7. NEXT GENERATION SEQUENCERS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Drug Discovery
  • 7.4. Biomarker Discovery
  • 7.5. Agriculture & Animal Research
  • 7.6. Others

8. NEXT GENERATION SEQUENCERS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Academics & Research Institutes
  • 8.5. Others

9. NEXT GENERATION SEQUENCERS MARKET BY GEOGRAPHY

  • 9.1. Global Overview
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia-Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Quest Diagnostics Incorporated
  • 11.2. ARUP Laboratories
  • 11.3. Applied Biological Materials, Inc. (ABM)
  • 11.4. Novogene Co., Ltd.
  • 11.5. Azenta Life Sciences (GENEWIZ)
  • 11.6. NanoString
  • 11.7. Illumina, Inc.
  • 11.8. PacBio
  • 11.9. Qiagen
  • 11.10. Thermo Fisher Scientific